LONDON, UK: The Royal Marsden NHS Foundation Trust, a world-leading specialist cancer center, has today announced a pioneering partnership with NTT DATA, a global leader in digital business and technology services, and CARPL.ai, a leading enterprise imaging artificial intelligence (AI) and machine learning operations (MLOps) platform. Together, they have designed and built an advanced AI-powered radiology analysis service for the development and evaluation of AI in medical imaging, designed to transform cancer research and, ultimately, improve patient outcomes.

AI’s potential to enhance the speed and accuracy of identifying imaging biomarkers has long been recognized. Funded by a three-year grant from the UK’s National Institute for Health and Care Research (NIHR), the service will be used for research at The Royal Marsden and the Institute of Cancer Research (ICR), including projects in collaboration with other research teams. This research initiative will focus on developing and evaluating AI algorithms to improve the accuracy of cancer evaluation, including sarcoma, lung, breast, brain, and prostate cancers. This will lead to faster response times, more accurate diagnoses, and better-targeted treatments.

The service runs on an MLOps clinical imaging platform, built and operated by NTT DATA. To enable this, NTT DATA developed a bespoke AI computing solution leveraging high-performance Dell servers and utilizing the latest GPU processing capacity orchestrated by the CARPL.ai platform, which helps test and manage AI algorithms and includes a large collection of radiology AI models.

NTT DATA is also providing specialist imaging AI consulting services, helping researchers at The Royal Marsden test and evaluate emerging AI tools in real clinical settings, while extracting maximum insight and value from both in-house and commercial algorithms.

“AI has immense potential to support clinicians in diagnosing and treating cancer earlier and more precisely,” said Professor Dow-Mu Koh, Professor in Functional Cancer Imaging and Consultant Radiologist in Functional Imaging at The Royal Marsden. “By working with NTT DATA and CARPL.ai, we’ve created a scalable research environment that allows us to explore the full potential of AI safely and in a way that could one day transform cancer diagnosis and treatment across the NHS.”

Minister of State for Health, Karin Smyth, said: “Our 10-Year Health Plan will modernize the NHS, replacing outdated systems with cutting-edge digital solutions. While this trial is in its early stages, it represents exactly the kind of collaboration between the NHS, industry, and academia that will help build a health service fit for the future. Early detection saves lives, and innovations like AI will transform how cancer is diagnosed and treated – helping patients receive faster and more effective care.”

Professor Mike Lewis, NIHR Scientific Director for Innovation, said: “Cancer is one of the biggest killers in the UK. That must change. This three-year grant will help researchers push the boundaries of AI-driven technology for cancer detection and diagnosis.

This AI-powered service represents the cutting edge of cancer research, and it is going to transform treatment, better support NHS staff, and ultimately change patients’ lives. It is another great example of how NIHR-funded and supported research will ensure the best care is there when patients need it.”

Tom Winstanley, Chief Technology Officer at NTT DATA UK & Ireland, commented: “This service is a great example of responsible innovation in practice, showing the ethical, secure use of AI in healthcare. We are very proud to support The Royal Marsden in pushing the boundaries of cancer research.”

Once the service is live, research teams at The Royal Marsden will be able to evaluate a range of AI models across several cancer types. These studies will generate critical insights into how AI can support clinical decision-making and shape future approaches to diagnosis and treatment. Through CARPL.ai’s centralized interface and built-in monitoring tools, the research teams will also be able to track model performance over time, enabling faster feedback loops between development and deployment – a crucial step towards clinical translation. NTT DATA will continue to work closely with The Royal Marsden to support this next phase of research, which will ultimately improve cancer care and patient outcomes.

The post The Royal Marsden NHS Foundation Trust Collaborates with NTT DATA and CARPL.ai appeared first on NRI News.

Currently active in Sahyadri’s Hadapsar and Deccan units, the Command Centre will be expanded across all Sahyadri hospitals in the next six months, ensuring seamless adoption of this transformative technology chain-wide.

On this announcement, Mr Abrarali Dalal, Managing Director and CEO of Sahyadri Hospitals Private Limited, said, “We are proud to launch Maharashtra’s first AI-Powered Command Centre, a revolutionary step in transforming patient care and safety. In partnership with Dozee, this initiative demonstrates our commitment to leveraging cutting-edge technology for proactive healthcare management, enabling real-time monitoring and seamless decision-making to safeguard the well-being of every patient.”

Speaking at the launch, Col (retd) Dr. Sunil Rao, Group COO of Sahyadri Hospitals Private Limited, stated: “At Sahyadri, we are committed to pushing the boundaries of healthcare innovation. The AI-powered Health Command Centre initiative embodies our vision of creating a safer, smarter, and more efficient healthcare ecosystem. By harnessing the power of AI, we aim to provide our patients with the highest level of care and improve clinical outcomes. With this initiative, Sahyadri reaffirms its position as a leader in tech-driven healthcare. By partnering with Dozee, we are creating a safer, smarter, and more connected future for our patients.”

Dr. Kapil Borawake, Director of Critical Care at Sahyadri Hospital added, “Patient safety is at the core of our operations. With this initiative, we are shifting from a reactive model to a predictive and preventive one. By utilizing real-time data and early warnings, our teams can address clinical deterioration before it becomes critical, saving lives and improving recovery outcomes. Doctors must adopt advanced AI-powered technologies like Dozee to enhance their clinical decision-making. In today’s evolving healthcare landscape, integrating AI into clinical practice is becoming essential to meet the high standards of care that patients now expect.”

The initiative equips non-ICU ward beds with Dozee’s state-of-the-art Remote Monitoring System (RMS) and Early Warning System (EWS), enabling continuous, real-time monitoring of vital parameters such as heart rate, respiration rate, blood pressure, SPO2 levels, temperature, and ECG. Dozee’s Early Warning System (EWS) tracks the trends of vital parameters and provides alerts to healthcare providers for early detection of patients’ clinical deterioration, enabling timely medical intervention. Dozee uses AI-based Ballistocardiography (BCG) for contactless vitals monitoring. Dozee’s technology is patented and made in India. Dozee’s innovative technology significantly impacts patient safety, clinical outcomes, and operational efficiency. A landmark study published in Frontiers in Medical Technology revealed that Dozee’s AI-powered Early Warning System (EWS) can predict patient deterioration up to 16 hours in advance, offering healthcare professionals critical time for early intervention.

Dr. Nikhila Juvvadi, MD – Medical Director – Dozee, added, “Partnering with Sahyadri Hospitals is a step forward in our mission to transform healthcare delivery. The AI-powered Health Command Centre is not just about technology—it’s about empowering healthcare professionals with the tools they need to provide the highest standard of care. This partnership underscores our shared vision of making patient safety a non-negotiable priority.”

This initiative positions Sahyadri as a beacon of innovation, setting a gold standard for hospitals nationwide striving to combine cutting-edge technology with compassionate care.

The post Sahyadri Hospitals Launches Maharashtra’s First AI-Powered Command Centre in Collaboration with Dozee appeared first on NRI News.

Clinical trials play a pivotal role in the development and evaluation of new research drugs for life-threatening conditions such as Cancer, Cardiac disease, liver disease, and numerous other ailments. These trials involve a meticulous process encompassing drug discovery, synthesis, screening for optimal efficacy, and stringent safety assessments. The journey from the initial stages of drug development to its availability in the market spans several years, typically ranging from 12 to 15 years. This comprehensive and time-consuming process is indispensable for ensuring the safety and efficacy of potential treatments.

Keeping this in mind, Sahyadri Hospitals has established an exceptional clinical research department, supported by a robust ethics committee. This dynamic team has been instrumental in conducting all phases of drug trials with unwavering dedication, systematicity, and efficiency. Over the past 13 years, Sahyadri Hospitals has successfully conducted more than 300 clinical trials, benefiting thousands of patients and contributing significantly to the advancement of medical knowledge.

“At Sahyadri Hospitals, we are dedicated to driving innovative research and transforming healthcare through our comprehensive clinical trials,” stated Dr. Deepa Divekar, Research Director, Sahyadri Hospitals Pvt Ltd. “By upholding the highest ethical standards and ensuring patient safety, we have become a preferred site for national and international pharmaceutical companies to conduct crucial trials on human subjects“

Clinical trials conducted at Sahyadri Hospitals have opened new avenues for medical advancements, offering hope to patients battling challenging health conditions. Through these trials, innovative research drugs have shown remarkable promise in transforming patient lives, delivering improved treatment outcomes, and paving the way for novel therapeutic approaches.

As Sahyadri Hospitals continues to drive healthcare innovation through its groundbreaking clinical trials, it remains committed to advancing patient care, striving for excellence, and shaping the future of medicine.

The post Sahyadri Hospitals Leads the Way in Clinical Trials for Revolutionary Research Drugs appeared first on NRI News.